Diurnal Group PLC Hardman Research: Infacort® - On track to market

TIDMDNL

Diurnal Group PLC

19 January 2017

Hardman Research: Infacort(R) - On track to market

Infacort(R) - On track to market: Diurnal is a clinical stage specialty pharmaceutical company focused on diseases of the endocrine system. It has two lead candidates - Infacort that completed its Phase III in Dec 2016 and Chronocort, currently in Phase III trials - targeted at rare diseases with unmet medical need, and is aiming to build a long-term 'Adrenal Franchise'. The completed Phase III trial confirmed that Infacort is well tolerated, achieved its primary endpoint and received the support of the parents and carers. Infacort will represent the first licenced cortisol replacement therapy for children and is on track to achieve market authorisation in late 2017 and sales in early 2018.

Please click here for the full report:

http://hardmanandco.com/docs/default-source/company-docs/diurnal-ltd-documents/19.01.17-infacort-on-track-to-market.pdf

 
 To contact us:      Contact: Dr Martin Hall 
  Hardman & Co        [e-mail] 
  11/12 Tokenhouse    Dr Dorothea Hill 
  Yard                [e-mail] 
  London              Dr Gregoire Pave 
  EC2R 7AS            [e-mail] 
                      Telephone: [phone] 
                      Follow us on Twitter @HardmanandCo 
 

www.hardmanandco.com

About Hardman & Co: For the past 20 years Hardman has been producing specialist research designed to improve investors' understanding of companies, sectors, industries and investment securities. Our analysts are highly experienced in their sectors, and have often been highly rated by professional investors for their knowledge. Our focus is to raise companies' profiles across the UK and abroad with outstanding research, investor engagement programmes and advisory services. Some of our notes have been commissioned by the company which is the subject of the note; this is clearly stated in the disclaimer where this is the case.

Hardman Research Ltd, trading as Hardman & Co, is an appointed representative of Capital Markets Strategy Ltd and is authorised and regulated by the Financial Conduct Authority; our FCA registration number is 600843. Hardman Research Ltd is registered at Companies House with number 8256259.

Our research is provided for the use of the professional investment community, market counterparties and sophisticated and high net worth investors as defined in the rules of the regulatory bodies. It is not intended to be made available to unsophisticated retail investors. Anyone who is unsure of their categorisation should consult their professional advisors. This research is neither an offer, nor a solicitation, to buy or sell any security. Please read the note for the full disclaimer.

This information is provided by RNS

The company news service from the London Stock Exchange

END

NRAVVLFFDFFFBBD

(END) Dow Jones Newswires

January 19, 2017 02:15 ET (07:15 GMT)